- Trials with a EudraCT protocol (6)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
6 result(s) found for: Radiation exposure monitoring.
Displaying page 1 of 1.
EudraCT Number: 2018-003811-23 | Sponsor Protocol Number: IMG-7289-CTP-102 | Start Date*: 2019-12-11 | |||||||||||||||||||||
Sponsor Name:Imago BioSciences, Inc. | |||||||||||||||||||||||
Full Title: A Multi-Center, Open Label Study to Assess the Safety, Steady State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients with Myelofibrosis | |||||||||||||||||||||||
Medical condition: Myelofibrosis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) IT (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004486-86 | Sponsor Protocol Number: SRA737-01 | Start Date*: 2016-04-25 | |||||||||||
Sponsor Name:Sierra Oncology, Inc. | |||||||||||||
Full Title: A Phase 1/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects with Advanced Cancer | |||||||||||||
Medical condition: Patients with histologically or cytologically proven advanced solid tumours, refractory to conventional treatment, or for which no conventional therapy is considered appropriate by the Investigator. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019595-79 | Sponsor Protocol Number: UMCNONCO200905 | Start Date*: 2010-10-15 | ||||||||||||||||
Sponsor Name:University Medical Centre Nijmegen | ||||||||||||||||||
Full Title: A randomised phase II study of radio-chemotherapy with or without panitumumab (Vectibix®) in irresectable squamous cell carcinoma or adenocarcinoma of the oesophagus (Panoramic) | ||||||||||||||||||
Medical condition: histology proven irresectable squamous cell or adenocarcinoma of the oesophagus | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-005150-62 | Sponsor Protocol Number: GALEN | Start Date*: 2013-05-14 | |||||||||||||||||||||
Sponsor Name:GELARC | |||||||||||||||||||||||
Full Title: A Phase Ib/II study of OBINUTUZUMAB combined with LENALIDOMIDE for the treatment of relapsed/refractory follicular and Aggressive (DLBCL and MCL) B-cell Lymphoma. | |||||||||||||||||||||||
Medical condition: Phase IB: CD20 positive Follicular Lymphoma, WHO grade 1, 2 or 3a relapsed/refractory after ≥1 prior R-containing regimen Phase II: CD20 positive follicular and agressive B-cell lymphoma (Diffus... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) BE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-006537-40 | Sponsor Protocol Number: VEG108838 | Start Date*: 2008-01-22 | |||||||||||
Sponsor Name:GlaxoSmithkline Research & Development Limited | |||||||||||||
Full Title: A Randomized, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib versus Lapatinib Monotherapy in Patients with ErbB2 over-expressing Inflammatory Breast Cancer | |||||||||||||
Medical condition: Relapsed or refractory inflammatory breast cancer with ErbB2 tumours. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) BE (Completed) DE (Prematurely Ended) GB (Completed) FR (Completed) ES (Completed) IT (Completed) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005933-12 | Sponsor Protocol Number: E7080-G000-201 | Start Date*: 2009-10-29 | |||||||||||
Sponsor Name:Eisai Limited | |||||||||||||
Full Title: Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified... | |||||||||||||
Medical condition: Medullary thyroid cancer [MTC] or radioiodine (131*I) refractory/resistant differentiated thyroid cancer[DTC]: Determine the pharmacokinetic (PK) profile and the pharmacokinetic/pharmacodynamic (PK... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) PL (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
